Nevertheless, human blood is a complex sample matrix that can be difficult to access the relevant stroke biomarkers, such as cellular fibronectin (c-Fn) and matrix metallopeptidase 9 (MMP9) [6,9,10]—strongly associated with ischemic stroke screening in clinical studies for more than five decades [11,12]. The gene discussed is MMP9; the disease is ischemic stroke.